Trade Beam Therapeutics Inc. - BEAM CFD

Trading Conditions

• TypeThis financial market is available for CFD trading.Learn more about:CFDs: CFD
• Spread: 0.1
• Long position overnight funding adjustmentLong position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.02237 %(-$4.47)Trade size with leverage ~ $20,000.00Money from leverage ~ $$19,000.00Go to platform: -0.02237%
• Short position overnight funding adjustmentShort position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position0.00015 %($0.03)Trade size with leverage ~ $20,000.00Money from leverage ~ $$19,000.00Go to platform: 0.00015%
• Overnight funding adjustment time: 22:00 (UTC)
• Currency: USD
• Min traded quantity: 1
• Margin: 5.00%
• Stock exchange: United States of America
• Commission on trade: 0%
• Guaranteed stop premiumA guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.: 1%

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.02237 %
  (-$4.47)

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: 0.00015 %
  ($0.03)

Key Stats

• Prev. Close: 25.78
• Open: 25.76
• 1-Year Change: 12.15%
• Day's Range: 25.76 - 26.54

Trade Beam Therapeutics Inc. - BEAM

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia. It also develops therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1a; and therapies for ocular and central nervous system disorders. The company has a strategic alliance with Boston Children''s Hospital; a research and clinical collaboration agreement with Magenta Therapeutics, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration with Apellis Pharmaceuticals, Inc. to apply base editing technology for discovering new treatments for complement-driven diseases. Beam Therapeutics Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.